目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Indication
1.2.2. Route of Administration
1.2.3. Vector Type
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.7. Primary Research
1.8. Information or Data Analysis
1.9. Market Formulation & Validation
1.10. Market Model
1.11. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Robust Gene Therapy Pipeline
3.2.1.2. Introduction Of Technological Advancements
3.2.1.3. Increasing Investment From Companies And Partnerships
3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
3.2.2. Market Restraint Analysis
3.2.2.1. Absence Of Effective Diagnosis Framework
3.2.2.2. High Prices Of Gene Therapy
3.2.3. Market Opportunity Analysis
3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
3.2.3.2. Facility Expansion For Cell And Gene Therapies
3.2.3.3. Technological Advancements In Manufacturing Vectors
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Route of Administration Business Analysis
4.1. Gene Therapy Market: Route of Administration Movement Analysis
4.2. Intravenous
4.2.1. Intravenous Market, 2018 - 2030 (USD Million)
4.3. Others
4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Indication Business Analysis
5.1. Gene Therapy Market: Indication Movement Analysis
5.2. Acute Lymphoblastic Leukemia
5.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
5.3. Inherited Retinal Disease
5.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
5.4. Large B-Cell Lymphoma
5.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
5.5. Melanoma (lesions)
5.5.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
5.6. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
5.6.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
5.7. Spinal Muscular Atrophy (SMA)
5.7.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Vector Type Business Analysis
6.1. Gene Therapy Market: Vector Type Movement Analysis
6.2. Lentiviral Vectors
6.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
6.3. Adeno-Associated Viral (Aav) Vectors
6.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
6.4. RetroVirus & gamma RetroVirus
6.4.1. RetroVirus & gamma RetroVirus market, 2018 - 2030 (USD Million)
6.5. Modified Herpes Simplex Virus
6.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
6.6. Adenovirus Vectors
6.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis
7.1. Gene Therapy Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target disease prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target disease prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Target disease prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Mexico Gene Therapy Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target disease prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target disease prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
7.3.4. Switzerland
7.3.4.1. Key Country Dynamics
7.3.4.2. Target disease prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Switzerland Gene Therapy Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target disease prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target disease prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
7.4.4. Australia
7.4.4.1. Key Country Dynamics
7.4.4.2. Target disease prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
7.5. Rest of the world
7.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Company Profiles
8.4.1. Amgen Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. F. Hoffmann-La Roche
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Gilead Sciences, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. bluebird bio, Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Bristol-Myers Squibb Company
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Legend Biotech.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. BioMarin.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. uniQure N.V.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Merck & Co.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Sarepta Therapeutics, Inc.
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Krystal Biotech, Inc
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. CRISPR Therapeutics.
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Tables
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Global Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 6 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 7 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 8 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
Table 9 North America Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 10 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 11 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 12 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 13 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 14 U.S. Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 15 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 16 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 17 Canada Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 18 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 19 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 20 Europe Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 21 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 22 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 23 Germany Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 24 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 25 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 26 UK Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 27 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 28 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 29 Switzerland Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 30 Switzerland Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 31 Switzerland Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 36 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 37 China Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 38 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 39 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 40 Japan Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 41 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 42 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 43 South Korea Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 44 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 45 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 46 Australia Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 47 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 48 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 49 RoW Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 50 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Market Formulation & Validation
Fig. 5 Gene Therapy Market Segmentation
Fig. 6 Porter’s Five Forces Analysis
Fig. 7 Regional Marketplace: Key Takeaways
Fig. 8 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
Fig. 9 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
Fig. 10 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
Fig. 11 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
Fig. 12 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
Fig. 13 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
Fig. 14 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
Fig. 15 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
Fig. 16 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
Fig. 17 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
Fig. 18 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
Fig. 19 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
Fig. 20 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
Fig. 21 Global Gene Therapy Market for Intravenous, 2018 - 2030 (USD Million)
Fig. 22 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
Fig. 23 Regional Outlook, 2022 & 2030
Fig. 24 North America Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 25 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 26 Canada Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 27 Europe Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 28 Germany Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 29 UK Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 30 Switzerland Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 31 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 32 Japan Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 33 China Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 34 Australia Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 35 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 36 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)